The Relationship between Selected Demographic Factors and Speech Organ Dysfunction in Sporadic ALS Patients

Pawlukowska, Wioletta; Baumert, Bartłomiej; Gołąb-Janowska, Monika; Meller, Agnieszka; Machowska-Sempruch, Karolina; Wełnicka, Agnieszka; Paczkowska, Edyta; Rotter, Iwona

doi:10.3390/medicina56080390

Cited by 3 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found substantial regional variations in the prevalence of cardiovascular conditions [170]. Hypertension was highest in France (57%) [171], Portugal (48%) [172,173], while the Netherlands [174] and Poland [175] reported lower rates at approximately 26% and 23% respectively. Chinese ALS patients had even lower prevalence of hypertension at 15% [176].…”

Section: Cardiovascular Comorbidities In Alsmentioning

confidence: 99%

Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

Bjelica,

Bartels,

Hesebeck-Brinckmann

et al. 2024

J Neurol

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive degeneration of both upper and lower motor neurons. A defining histopathological feature in approximately 97% of all ALS cases is the accumulation of phosphorylated trans-activation response (TAR) DNA-binding protein 43 protein (pTDP-43) aggregates in the cytoplasm of neurons and glial cells within the central nervous system. Traditionally, it was believed that the accumulation of TDP-43 aggregates and subsequent neurodegeneration primarily occurs in motor neurons. However, contemporary evidence suggests that as the disease progresses, other systems and brain regions are also affected. Despite this, there has been a limited number of clinical studies assessing the non-motor symptoms in ALS patients. These studies often employ various outcome measures, resulting in a wide range of reported frequencies of non-motor symptoms in ALS patients. The importance of assessing the non-motor symptoms reflects in a fact that they have a significant impact on patients’ quality of life, yet they frequently go underdiagnosed and unreported during clinical evaluations. This review aims to provide an up-to-date overview of the current knowledge concerning non-motor symptoms in ALS. Furthermore, we address their diagnosis and treatment in everyday clinical practice.

show abstract

Section: Cardiovascular Comorbidities In Alsmentioning

confidence: 99%

Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

Bjelica,

Bartels,

Hesebeck-Brinckmann

et al. 2024

J Neurol

View full text Add to dashboard Cite

show abstract

“…Speech disorders arise from bulbar involvement, leading to changes in four areas: articulation, respiration, phonation, and resonance [ 3 ]. It has been shown that speech deterioration associated with the length of phonation and voice loudness is more dynamic in men [ 4 ]. Changes occurring in these areas have serious consequences on the functioning of patients with ALS.…”

Section: Introductionmentioning

confidence: 99%

Humoral Influence of Repeated Lineage-Negative Stem/Progenitor Cell Administration on Articulatory Functions in ALS Patients

Sobuś

Baumert

Pawlukowska

et al. 2020

Stem Cells International

Self Cite

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) remains a fatal, neurodegenerative disease frequently leading to dysarthria and impaired swallowing. Better understanding of ALS pathophysiology is prompting the use of humoral cell therapies. Hence, a repeated cellular therapy was applied to ALS patients as an attempt to prevent speech deterioration. Autologous bone marrow-derived lineage-negative (Lin−) cells were intrathecally administered three times at six-week intervals to 42 sporadic ALS patients. Patients were examined for articulatory functions using subjective (VHI) and objective (FDA) scales. Selected trophic, proinflammatory factors and expression profiles of miRNA were measured in cerebrospinal fluid (CSF) and plasma by multiplex Luminex and q-PCR in different timepoints. Of the 42 patients who received the Lin− cells, 6 showed improvement in articulatory functions, 27 remained stable, and 9 deteriorated after 18 weeks of therapy according to FDA scale. Clinical improvement was particularly evident by the 7th day of each cell application and concerned better cough and swallow reflex, soft palate, laryngeal time, pitch, and volume. These results correlated with significant changes in the concentration of various trophic and proinflammatory factors and miRNA expression profiles. A multiple application of Lin− cells proved to be safe and feasible. The repeated procedure can potentate a humoral effect and prevent speech deterioration. A short-lasting trophic effect of each Lin− cells administration was observed on local and systemic level. However, further in-depth studies are necessary to sustain the beneficial effect.

show abstract

Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review

2022

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

The Relationship between Selected Demographic Factors and Speech Organ Dysfunction in Sporadic ALS Patients

Cited by 3 publications

References 50 publications

Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions

Humoral Influence of Repeated Lineage-Negative Stem/Progenitor Cell Administration on Articulatory Functions in ALS Patients

Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review

Contact Info

Product

Resources

About